Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage Response*
暂无分享,去创建一个
Yves Pommier | Y. Pommier | N. Caplen | T. Jones | Yong-Wei Zhang | Yong-Wei Zhang | Scott E Martin | Natasha J Caplen | Tamara L Jones
[1] P. Vandenabeele,et al. Connexin-related signaling in cell death: to live or let die? , 2009, Cell Death and Differentiation.
[2] H. Niida,et al. Essential role of Chk1 in S phase progression through regulation of RNR2 expression. , 2008, Biochemical and biophysical research communications.
[3] M. Grever,et al. Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia , 2008, Clinical Cancer Research.
[4] F. Torti,et al. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma , 2008, Cancer Chemotherapy and Pharmacology.
[5] B. Teicher. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. , 2008, Biochemical pharmacology.
[6] Y. Pommier,et al. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. , 2007, Cancer research.
[7] A. Sartorelli,et al. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. , 2007, The Journal of clinical investigation.
[8] Y. Pommier,et al. The Intra-S-Phase Checkpoint Affects both DNA Replication Initiation and Elongation: Single-Cell and -DNA Fiber Analyses , 2007, Molecular and Cellular Biology.
[9] Y. Rustum,et al. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer , 2007, Cancer Chemotherapy and Pharmacology.
[10] Mark E. Davis,et al. Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo , 2007, Clinical Cancer Research.
[11] J. Weinstein,et al. Multiplexing siRNAs to compress RNAi-based screen size in human cells , 2007, Nucleic acids research.
[12] A. Sartorelli,et al. Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stress. , 2007, Biochemical pharmacology.
[13] A. Koc,et al. Checkpoint deficient rad53-11 yeast cannot accumulate dNTPs in response to DNA damage. , 2007, Biochemical and biophysical research communications.
[14] Marcus B Smolka,et al. Mechanism of Dun1 Activation by Rad53 Phosphorylation in Saccharomyces cerevisiae* , 2007, Journal of Biological Chemistry.
[15] B. Sclavi,et al. Ribonucleotide reductase and the regulation of DNA replication: an old story and an ancient heritage , 2007, Molecular microbiology.
[16] M. Tyers,et al. Ccr4 contributes to tolerance of replication stress through control of CRT1 mRNA poly(A) tail length , 2006, Journal of Cell Science.
[17] Y. Pommier,et al. Defective Mre11-dependent Activation of Chk2 by Ataxia Telangiectasia Mutated in Colorectal Carcinoma Cells in Response to Replication-dependent DNA Double Strand Breaks* , 2006, Journal of Biological Chemistry.
[18] Y. Pommier. Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.
[19] K. Kohn,et al. p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine , 2006, Oncogene.
[20] S. Elledge,et al. Control of ribonucleotide reductase localization through an anchoring mechanism involving Wtm1. , 2006, Genes & development.
[21] Y. Shaul,et al. Autorepression of Rfx1 Gene Expression: Functional Conservation from Yeast to Humans in Response to DNA Replication Arrest , 2005, Molecular and Cellular Biology.
[22] R. Schilsky,et al. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] D. Loegering,et al. The Role of Checkpoint Kinase 1 in Sensitivity to Topoisomerase I Poisons* , 2005, Journal of Biological Chemistry.
[24] N. Curtin,et al. Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM , 2004, Cancer Research.
[25] G. Schwartz,et al. Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe , 2004, Cancer Research.
[26] A. Sartorelli,et al. Stable Suppression of the R2 Subunit of Ribonucleotide Reductase by R2-targeted Short Interference RNA Sensitizes p53(–/–) HCT-116 Colon Cancer Cells to DNA-damaging Agents and Ribonucleotide Reductase Inhibitors* , 2004, Journal of Biological Chemistry.
[27] R. Hettich,et al. Identification of Phosphorylation Sites on the Yeast Ribonucleotide Reductase Inhibitor Sml1* , 2004, Journal of Biological Chemistry.
[28] A. Chabes,et al. S Phase-specific Transcription of the Mouse Ribonucleotide Reductase R2 Gene Requires Both a Proximal Repressive E2F-binding Site and an Upstream Promoter Activating Region* , 2004, Journal of Biological Chemistry.
[29] L. Doyle,et al. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.
[30] Lijun Xue,et al. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. , 2003, Cancer research.
[31] K. Kunugi,et al. Overexpression of the R2 Subunit of Ribonucleotide Reductase in Human Nasopharyngeal Cancer Cells Reduces Radiosensitivity , 2003, Cancer journal.
[32] Y. Pommier,et al. Phosphorylation of Histone H2AX and Activation of Mre11, Rad50, and Nbs1 in Response to Replication-dependent DNA Double-strand Breaks Induced by Mammalian DNA Topoisomerase I Cleavage Complexes* , 2003, Journal of Biological Chemistry.
[33] A. Fedier,et al. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. , 2003, International journal of oncology.
[34] Jiri Bartek,et al. Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.
[35] C. Stevens,et al. Chk2 activates E2F-1 in response to DNA damage , 2003, Nature Cell Biology.
[36] S. Chellappan,et al. Differential regulation of Rb family proteins and prohibitin during camptothecin-induced apoptosis , 2002, Oncogene.
[37] Xiang Wang,et al. CHK1-Regulated S-phase Checkpoint Response Reduces Camptothecin Cytotoxity , 2002, Cell cycle.
[38] Rodney Rothstein,et al. The Dun1 checkpoint kinase phosphorylates and regulates the ribonucleotide reductase inhibitor Sml1 , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[39] W. Cliby,et al. S Phase and G2 Arrests Induced by Topoisomerase I Poisons Are Dependent on ATR Kinase Function* , 2002, The Journal of Biological Chemistry.
[40] Y. Nakamura,et al. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. , 2001, Cancer research.
[41] J. Nevins,et al. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. , 2001, Genes & development.
[42] R. Rothstein,et al. The ribonucleotide reductase inhibitor Sml1 is a new target of the Mec1/Rad53 kinase cascade during growth and in response to DNA damage , 2001, The EMBO journal.
[43] W. Brownell,et al. Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems. , 2000, Genes & development.
[44] S. Elledge,et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.
[45] Y. Pommier,et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. , 1999, Cancer research.
[46] Y. Pommier,et al. Apoptotic response to camptothecin and 7‐hydroxystaurosporine (UCN‐01) in the 8 human breast cancer cell lines of the NCI anticancer drug screen: Multifactorial relationships with topoisomerase i, protein kinase C, Bcl‐2, p53, MDM‐2 and caspase pathways , 1999, International journal of cancer.
[47] S. Elledge,et al. The DNA Replication and Damage Checkpoint Pathways Induce Transcription by Inhibition of the Crt1 Repressor , 1998, Cell.
[48] R Rothstein,et al. A suppressor of two essential checkpoint genes identifies a novel protein that negatively affects dNTP pools. , 1998, Molecular cell.
[49] K. Kohn,et al. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. , 1997, Cancer research.
[50] Y. Pommier,et al. Cellular Resistance to Camptothecins , 1996, Annals of the New York Academy of Sciences.
[51] K. Kohn,et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. , 1996, Cancer research.
[52] J. Nevins,et al. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes , 1995, Molecular and cellular biology.
[53] S. Elledge,et al. The SAD1/RAD53 protein kinase controls multiple checkpoints and DNA damage-induced transcription in yeast. , 1994, Genes & development.
[54] S. Elledge,et al. DUN1 encodes a protein kinase that controls the DNA damage response in yeast , 1993, Cell.
[55] L. Liu,et al. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. , 1993, Cancer research.
[56] S. Elledge,et al. DNA damage and cell cycle regulation of ribonucleotide reductase , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.
[57] A. Gräslund,et al. EPR stopped-flow studies of the reaction of the tyrosyl radical of protein R2 from ribonucleotide reductase with hydroxyurea. , 1992, Biochemical and biophysical research communications.
[58] Y. Pommier,et al. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. , 1989, Cancer research.
[59] L. Liu,et al. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.
[60] Y. Engström,et al. Immunocytochemical evidence for the cytoplasmic localization and differential expression during the cell cycle of the M1 and M2 subunits of mammalian ribonucleotide reductase. , 1988, The EMBO journal.
[61] H. Hansson,et al. Localization of ribonucleotide reductase in mammalian cells. , 1984, The EMBO journal.
[62] Y. Pommier,et al. Repair of topoisomerase I-mediated DNA damage. , 2006, Progress in nucleic acid research and molecular biology.
[63] C. Bailly. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. , 2003, Critical reviews in oncology/hematology.
[64] L. Liu,et al. Tumor cell death induced by topoisomerase-targeting drugs. , 2001, Annual review of pharmacology and toxicology.
[65] S. Chatterjee,et al. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. , 1994, Oncology research.